Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Tempest Therapeutics Inc.
Headquarters: San Francisco, CA, United States of America
Website: http://www.tempesttx.com/
Year Founded: 2011
Status: Public
Industry Sector: HealthTechnology
CEO: Stephen R. Brady
Number Of Employees: 25
Enterprise Value: $8,381,001
PE Ratio: -0.48
Exchange/Ticker 1: NASDAQ:TPST
Exchange/Ticker 2: N/A
Latest Market Cap: $32,679,798
BioCentury | Aug 22, 2024
Management Tracks
Dimitrios Arkilo named CMO of Actio
Plus: Coya promotes Arun Swaminathan to CEO, and updates from Tempest and Incyclix
BioCentury | May 2, 2024
Management Tracks
McDonnell now CEO of Agilent
Plus: Dubensky to lead ImmuneSensor and updates from NORD and Epsilogen
BioCentury | Oct 12, 2023
Politics, Policy & Law
Oct. 11 Quick Takes: European Parliament proposes amendments to pharma legislation
Plus: Early stop for Novo’s kidney outcomes study of semaglutide; Agomab raises $100M series B; and updates from MinervaX, FDA, ARPA-H, Tempest, Kanvas-Federation Bio
BioCentury | Nov 16, 2021
Management Tracks
End of an era at Biogen as R&D head Sandrock readies to retire
Plus: Levin-Allerhand joins Flagship, and updates from Alchemab, Agios, Actym, Gilgamesh and more
BioCentury | Jun 25, 2021
Finance
Hat trick for Versant as Graphite follows Monte Rosa, Century to NASDAQ
Firm’s portfolio companies quickly lining up to tap biotech’s yawning IPO window
BioCentury | Mar 30, 2021
Deals
March 29 Quick Takes: SPAC carrying SomaLogic to NASDAQ; plus LianBio-Tarsus, Qihan, Biohaven, Tempest
SomaLogic Inc. is merging with CM Life Sciences II, a SPAC sponsored by Casdin Capital and Corvex Management (NASDAQ:CMIIU). The deal is expected to give the proteomics company up to $651 million
BioCentury | Nov 3, 2020
Management Tracks
Baldry joins Freeline as chief commercial officer; plus moves at X4, Cullinan, Surrozen, QurAlis, NantKwest, Seres, Canbridge, SQZ, AM-Pharma, Tempest and more
Gene therapy developer Freeline Therapeutics Holdings plc (NASDAQ:FRLN) hired Mark Baldry as chief commercial officer. He previously held the same role at Wave Life Sciences Ltd. (NASDAQ:WVE).
BioCentury | Mar 29, 2019
Targets & Mechanisms
AACR moves in a myeloid direction
A survey of the hot topics covered in this year’s AACR abstracts
BioCentury | Nov 15, 2018
Product R&D
Tempest takes PPAR alpha into cancer
Why Tempest thinks PPARα could succeed in cancer where IDO failed
Items per page:
1 - 10 of 17